Therapeutic Solutions International Inc (TSOI)

[centsability4me]

PLURIPOTENT STEM CELL DERIVED DENDRITIC CELLS AND ENGINEERED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY

https://patents.justia.com/patent/20220298491
(New TSOI patent published 9/22/22)

Abstract
Disclosed are populations of dendritic cells generated from stem cells capable of inducing immunity towards cancer. In one embodiment said dendritic cells are generated from allogeneic inducible pluripotent stem cells, for some uses, said pluripotent stem cells are genetically engineered/edited to induce cancer specific immunity and/or resist immunosuppressive effect of tumor derived microenvironment. In one embodiment pluripotent stem cells are transfected with cancer stem cell antigens such as BORIS and/or NR2F6.

Claims

1. A method of generating a dendritic cell from a stem cell possessing enhanced ability to induce anticancer immunity, wherein said dendritic cell is obtained by the process of: a) selecting a stem cell population; b) genetically modifying said stem cell population to endow enhanced anticancer activity towards said stem cell; c) differentiating said stem cell into a dendritic cell population.

2. The method of claim 1, wherein said stem cell is an inducible pluripotent stem cell.

3. The method of claim 2, wherein said inducible pluripotent stem cell is generated by transfection of mammalian cells with a pluripotency factor, wherein said pluripotency factor gene is one or more genes selected from the group consisting of oct3/4, sox2, klf4, c-myc, lin28, nanog, glis-1, bcl2, bclxl, AIRE, HIF-1 alpha, survivin, livin and bclx.

4. The method of claim 3, wherein, mammalian cells are further provided with: a. a third nucleic acid encoding from 2 to 7 distinct gRNAs, each gRNA comprising a DNA-binding segment and a polypeptide-binding segment, wherein the DNA-binding segment binds the promoter region of a second endogenous pluripotency factor gene; and b. a fourth nucleic acid encoding from 2 to 7 distinct gRNAs, each gRNA comprising a DNA-binding segment and a polypeptide-binding segment, wherein the DNA-binding segment binds the promoter region of a third endogenous pluripotency factor gene; wherein the transcriptional modulator binds the polypeptide-binding segment of the gRNAs encoded by the third and fourth nucleic acids.

5. The method of claim 4, wherein: (i) the DNA-binding segment of each the gRNAs encoded by the first nucleic acid is complementary to at least a portion of the promoter region of a mammalian oct3/4 gene; (ii) the DNA-binding segment of each the gRNAs encoded by the third nucleic acid is complementary to at least a portion of the promoter region of a mammalian sox2 gene; and (iii) the DNA-binding segment of each the gRNAs encoded by the fourth nucleic acid is complementary to at least a portion of the promoter region of a mammalian klf4 gene.

6. The method of claim 1, wherein said pluripotent stem cell is transfected with a tumor antigen in order to induce immunity towards said tumor antigen.

7. The method of claim 6, wherein said tumor antigen is CTCFL.

8. The method of claim 6, wherein said tumor antigen is PDGFR-beta.

9. The method of claim 6, wherein said tumor antigen is PAP.

10. The method of claim 6, wherein said tumor antigen is MAD-CT-2.

11. The method of claim 6, wherein said tumor antigen is Tie-2.

12. The method of claim 6, wherein said tumor antigen is PSA.

13. The method of claim 6, wherein said tumor antigen is protamine.

14. The method of claim 6, wherein said tumor antigen is legumain.

15. The method of claim 6, wherein said tumor antigen is endosialin.

16. The method of claim 6, wherein said tumor antigen is PSMA.

17. The method of claim 6, wherein said tumor antigen is carbonic anhydrase IX.

18. The method of claim 6, wherein said tumor antigen is STn.

19. The method of claim 6, wherein said tumor antigen is Page4.

20. The method of claim 6, wherein said tumor antigen is proteinase 3.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application Ser. No. 63/161,526, filed on Mar. 16, 2021, entitled "Pluripotent Stem Cell Derived Dendritic Cells and Engineered Dendritic Cells for Cancer Immunotherapy", which is incorporated herein by reference in its entirety